Navigation Links
HistoRx and Lilly Extend, Expand AQUA(R) Analysis Partnership
Date:3/26/2008

-Agreement provides Lilly researchers broad access to HistoRx AQUA(R)

technology for tissue biomarker analysis-

NEW HAVEN, Conn., March 26 /PRNewswire/ -- HistoRx, Inc. announced today that it has signed a three-year agreement with Eli Lilly and Company (NYSE: LLY) to make the HistoRx AQUA(R) technology for tissue biomarker analysis widely available to Lilly researchers and clinicians involved in drug discovery, preclinical research, and clinical development. The agreement extends and significantly expands the scope of the collaboration established by HistoRx and Lilly in 2005 to apply the HistoRx AQUA(R) technology to help advance select Lilly pharmaceutical development programs. Under the new agreement, HistoRx will provide Lilly researchers broad access to the AQUA(R) technology for tissue biomarker analysis, and HistoRx will develop customized AQUA(R) analysis-based immunohistochemical assays for use in Lilly drug discovery and development projects. HistoRx has the option to commercialize the assays and reagents developed during the course of the partnership for clinical use as predictive diagnostics.

HistoRx provides pharmaceutical and biotechnology companies access to AQUA(R) technology through partnership agreements by which HistoRx works with the company in applying its hallmark quantitative, multiparametric, tissue- based biomarker measurement and analysis to drug development programs, virtually eliminating the subjective interpretation inherent in conventional immunohistochemical methods. In the course of the partnership, HistoRx develops AQUA(R) analysis-based diagnostic assays that are linked to its partners' drugs in development. HistoRx may then commercialize these assays as prognostic tests or as companion diagnostics.

HistoRx currently has 10 such partnerships with leading pharmaceutical companies such as Lilly involving therapeutics in multiple stages of development. Researchers at these companies are using AQUA(R) analysis-based assays to identify correlations of biomarker expression with clinical outcomes, including drug dosing effects, therapeutic mechanism of action, drug safety, and therapeutic efficacy.

"We consider this expanded agreement with Lilly, one of the world's leading innovation-driven pharmaceutical companies, to be a tremendous validation of the HistoRx AQUA(R) technology," said Rana K. Gupta, CEO of HistoRx. "By revealing stronger, more reliable statistical correlations linking protein biomarker expression with prediction of patient response to therapy and disease outcome, we expect this ongoing partnership to continue providing a substantial boost to Lilly's drug research and development programs."

About HistoRx (http://www.historx.com)

HistoRx, Inc. is a leader in the emerging field of tissue-based diagnostic products for targeted patient treatment. The company's products and services are based on proprietary AQUA(R) technology, the first platform capable of measuring biomarker concentration with subcellular resolution in tissue sections in a fully standardized and automated manner. HistoRx partners with pharmaceutical and biotechnology companies to generate precise and cost- effective answers about the safety and effectiveness of targeted therapeutics in development for cancer and other diseases. These partnerships provide the foundation for HistoRx to develop companion diagnostic tests that will be co- marketed with partners' targeted therapeutics. HistoRx also pursues internal programs to develop proprietary diagnostics that will enable improved treatment decisions in cancer care.

CONTACT:

Mary Moynihan

M2Friend Biocommunications

(802) 951-9600

mary@m2friend.com


'/>"/>
SOURCE HistoRx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lilly Announces Termination of AIR Insulin Program
2. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
3. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
4. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
5. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
6. Lilly Declares Fourth-Quarter Dividend
7. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
8. Neptune Technologies expands into medicinal markets in Asia Pacific
9. CMPMedica Expands SearchMedica.com with Multiple Additional Vertical Search Applications co-developed with Convera(R)
10. Nova Biosource Fuels Expands Senior Executive Team
11. FDA Clears Expanded Use of Xofts Axxent(R) Electronic Brachytherapy System for all Radiation Therapy Indications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Global Stem Cells Group ... Ross is the founder of GSCG affiliate Kimera Labs in Miami. , In 2004, ... hematopoietic stem cell transplantation for hematologic disorders and the suppression of graft vs. host ...
(Date:4/26/2016)... ... 26, 2016 , ... BaseHealth , the comprehensive predictive ... as Chief Business Officer. Arianpour, a genomics pioneer and visionary commercial leader with ... recently Chief Commercial Officer of Pathway Genomics. He has held senior executive roles ...
(Date:4/26/2016)... ... 26, 2016 , ... BioFactura, Inc ., a biopharmaceutical research and manufacturing ... Healthy investor interest drove significant oversubscription of the original $1.5M target. The funds ... the advanced preclinical stages. , Chief Executive Officer and President, Darryl Sampey ...
(Date:4/26/2016)... 2016 genae, a Contract Research ... announced today the appointment of Prof. Dr. Jörn Balzer ... responsibilities will include all clinical, safety and risk management ... privileged and honored with the acceptance of Prof. Balzer ... CEO at genae. "Prof. Balzer,s impressive and extensive background ...
Breaking Biology Technology:
(Date:3/9/2016)... Germany , March 9, 2016 ... country,s government identified that more than 23,000 public service ... or had been receiving their salary unlawfully.    ... African country,s government identified that more than 23,000 public ... name or had been receiving their salary unlawfully.    ...
(Date:3/3/2016)... March 3, 2016  FlexTech, a SEMI Strategic Association ... Innovation, Research & Development, Leadership in Education, and, in ... the 9 th year of the FLEXI Awards ... and individuals from past years . Judging was ... pre-described set of criteria, by a panel of non-affiliated, ...
(Date:3/2/2016)... DUBLIN , March 2, 2016 /PRNewswire/ ... has announced the addition of the  "Global ... to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... sector to grow at a CAGR of ... http://www.researchandmarkets.com/research/wzwqtz/global_biometrics ) has announced the addition ...
Breaking Biology News(10 mins):